Management of Breakthrough Bleeding During Extended Therapy Use With NuvaRing┬«
Information source: Scott and White Hospital & Clinic
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Breakthrough Bleeding; Breakthrough Spotting
Intervention: remove ring if bleeding or spotting occurs more than 5 days (Other); If bleeding does not remove ring (Other)
Sponsored by: Scott and White Hospital & Clinic
Official(s) and/or principal investigator(s):
Patricia Sulak, MD, Principal Investigator, Affiliation: Scott and White Hospital and Clinic
The purpose of this research study is to evaluate the best way to manage breakthrough
spotting and bleeding during an extended use regimen of NuvaRing«. Ease of use and
acceptability of a flexible regimen of NuvaRing« will also be evaluated. A comparison of
cyclic mood symptoms, pelvic pain, and headaches will be made between a standard 21/7 regimen
and an extended regimen.
Official title: The Frequency and Management of Breakthrough Bleeding During Extended Therapy With the Transvaginal Contraceptive Ring
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Primary outcome: a comparison of days and extent per day of bleeding and spotting within subjects for continuous use pattern of nuvaring.
a comparison of choice to switch patterns or stick with randomized pattern for second phase of study (2nd 6 month interval).
comparisons of all symptoms (pelvic pain, headaches, moodiness, and pain medication use) both within subjects during different treatment intervals and between subject groups.
Hormonal contraception is undergoing a change away from a 21/7 day regimen where a woman
utilizes a combination estrogen and progestin therapy for 21 days followed by 7 days of a
hormone-free interval (HFI). It is well documented that women may experience a higher
incidence of mood changes, headaches and cramping that begin prior to and during this 7 day
HFI. By reducing the HFI and extending the active combination contraceptive therapy, it is
hoped that women will experience greater satisfaction with their contraceptive regimen and
will experience fewer negative side effects associated with a HFI.
The most common reason for discontinuation of an extended contraception regimen is irregular
bleeding. The purpose of this research study is to evaluate the best way to manage this
breakthrough spotting and bleeding. Ease of use and acceptability of a flexible regimen of
NuvaRing will also be evaluated. A comparison of cyclic mood symptoms, pelvic pain, and
headaches will be made between a standard 21/7 regimen and an extended regimen.
The contraceptive ring used in this study contains both an estrogen (ethinyl estradiol) and a
progestin (etonogestrel). These are synthetic (man-made) hormones. The amount of ethinyl
estrogen released into the bloodstream each day is 120mcg and the amount of etonogestrel is
150mcg. The NuvaRing┬«, by Organon, is FDA approved for contraception, but is not approved
for use in an extended regimen. Therefore its use in this study is considered
Minimum age: 18 Years.
Maximum age: 45 Years.
- Age 18-45 years of age
- Currently utilizing combination estrogen/progestin contraception for a period of at
least 2 months or 1 month if previously using a progestin only pill.
- Body Mass Index (BMI) of 38 or greater
- Anyone who should not be using hormonal contraception due to contraindications
- Anyone who smokes > 10 cigarettes per day or if 35 years old or older smokes any
- Anyone who is taking antiretroviral therapy (due to many drug interactions)
- Women using other estrogen-containing products or herbal products that contain
- Known or suspected pregnancy, or desiring pregnancy in the next year
Additionally, NuvaRing┬« should not be used in women who currently have the following
- A past history of deep vein thrombophlebitis or thromboembolic disorders
- Cerebral vascular or coronary artery disease (current or history)
- Valvular heart disease with thrombogenic complications
- Severe hypertension
- Diabetes with vascular involvement
- Headaches with focal neurological symptoms
- Major surgery in patients with prolonged immobilization
- Known or suspected carcinoma of the breast or personal history of breast cancer
- Carcinoma of the endometrium or other known or suspected estrogen dependent neoplasia
- Undiagnosed abnormal genital bleeding
- Cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use
- Hepatic tumors (benign or malignant) or active live disease
- Hypersensitivity to any components of NuvaRing┬«
Locations and Contacts
Scott & White Hospital and Clinic, Temple, Texas 76508, United States
Starting date: May 2006
Ending date: May 2008
Last updated: May 20, 2008